Earnings and Investment

April 16th 2025

RenovoCath is designed to deliver diagnostic and therapeutic agents directly to targeted tissues, offering a localized approach to treatment that can minimize systemic exposure.

April 15th 2025

$8 billion division grew 4.1% for the quarter

April 8th 2025

Trump's tariff announcements led to a stock market meltdown with trillions of dollars of losses from retirement accounts — at least on paper. What now? Here's what investors should consider.

April 4th 2025

The company also expects to submit its application for 510(k) clearance for its OneRF Trigeminal Nerve Ablation System in May, sooner than expected.